Document Type
Letter to the Editor
Publisher
Higher Education Pres
Faculty
Faculty of Health, Engineering and Science
School
School of Medical Sciences
RAS ID
19927
Abstract
hCLP46 (human CAP10-like protein 46 kDa) was initially isolated and identified from human acute myeloid leukemia transformed from myelodysplastic syndrome (MDS-AML) CD34+ cells (Teng et al., 2006) and we demonstrated previously that hCLP46 is abnormally expressed in many hematopoietic malignancies (Wang et al., 2010). Studies fromits Drosophila homolog, Rumi, suggested that Notch is a potential target of hCLP46 (Acar et al., 2008). We also found that overexpression of hCLP46 enhances Notch activation and regulates cell proliferation in a cell type-dependent manner (Ma et al., 2011; Chu et al., 2013). However, hCLP46−/− embryos show more severe phenotypes compared to those displayed by other global regulators of canonical Notch signaling, suggesting that hCLP46 is likely to have additional important targets during mammalian development (Fernandez- Valdivia et al., 2011). Based on the crosstalk between Notch and the transforming growth factor-β (TGF-β) signaling, we proposed that hCLP46 might be involved in TGF-β signal regulation, but the detail mechanism remains unclear.
DOI
10.1007/s13238-015-0174-0
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Comments
Xing, Y., Chu, Q., Feng, R., Wang, W., Liu, L., & Lu, Z. (2015). hCLP46 increases Smad3 protein stability via inhibiting its ubiquitin-proteasomal degradation. Protein & cell, 6(10), 767-770. Available here